Join the club for FREE to access the whole archive and other member benefits.

Juvenescence

Developing therapies against different aging related diseases.

Juvenescence is a bio-pharma development company developing therapies focused on allowing people worldwide to live longer, healthier lives. We have raised USD $65M to build an ecosystem and pipeline of assets targeting ageing, age-related disease and regeneration.

Visit website: https://www.juvlabs.com/

 juvlabs

 juvenescence1

 juvlabs

Details last updated 04-May-2019

Juvenescence News

Reason reports back from Age-Related Disease Therapeutics Summit 2023

Reason reports back from Age-Related Disease Therapeutics Summit 2023

Fight Aging! - 16-Jun-2023

Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few years

Summary of Jim Mellon presentation at Longevity Med Summit

Summary of Jim Mellon presentation at Longevity Med Summit

Live Forever Club - 19-May-2023

Urges individuals with resources and a desire to contribute positively to humanity to invest in the longevity industry

AgeX credit running out with substantial doubt it can continue

AgeX credit running out with substantial doubt it can continue

FierceBiotech - 15-Aug-2022

Let's hope their research is either successful for the company or its successors

JuvLife Division raises 3.7 million euros for making antiaging product with Chrysea

JuvLife Division raises 3.7 million euros for making antiaging product with Chrysea

Longevity Technology - 13-Jun-2022

Metabolites induce autophagy, stimulate cellular regeneration for healthy ageing

Selah Therapeutics launched to focus on ketone-based therapies for heart disease

Selah Therapeutics launched to focus on ketone-based therapies for heart disease

Longevity Technology - 13-May-2022

Treatment options for diseases of aging - from the makers of metabolic switch


Display all news

Juvenescence is also referenced in the following:

BHB Therapeutics

Developing preventative medicines for age-related disease using ketone bodies

Jeff Madwed

Executive Director of Juvenescence’s JuvTherapeutics Division

Napa Therapeutics

Focused on a novel target linked to one of the fundamental processes of aging

Selah Therapeutics

Company focused on novel ketone-based therapies for the treatment of heart diseases

Juvenescence Creations

Investing in the Future of Longevity – the Ketone Chapter

10-May-2022

Juvenescence webinar about the latest research and developments on future of longevity investment

People at Juvenescence

Gregory Bailey

CEO at Juvenescence and chairman of Portage Biotech

Jim Mellon

British entrepreneur, author and philanthropist with interests across a number of industries

Alexander Pickett

Managing Director at Juvenescence

David Gill

Chief Financial Officer at Juvenescence

David Roblin

Chief Operating Officer and CEO of Therapeutics Division at Juvenescence

Colin Watts

CEO at Juvenescence Life.

Ellen Donnelly

Chief Executive Officer of the Epigenetics Division of Juvenescence Limited

Topics mentioned on this page:
Ageing Research